Sanofi
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Sanofi reported 9 stock positions worth $174.4 million. Its top holding was Meiragtx (MGTX) at 42.6% of the portfolio, followed by Novavax (NVAX, 31.7%) and Inhibrx Biosciences (INBX, 10.2%).
- Most Recent 13F
- Q2 2026
- Location
- Paris, I0
- CIK
- 0001121404
- Portfolio Value
- $174.4M (Q4 2024)
- SEC Filing
- 0000950123-25-002465 ↗ filed Feb 14, 2025
Holdings Value
Holdings 9 stocks · $174.4M
| MGTX Meiragtx Holdings PLC | 42.60% | 12,197,737 | $74.3M | — |
| NVAX Novavax Inc. | 31.73% | 6,880,481 | $55.3M | — |
| INBX Inhibrx Biosciences Inc. | 10.23% | 1,157,926 | $17.8M | — |
| ANAB Anaptysbio Inc. | 6.24% | 821,917 | $10.9M | — |
| IGMS Igm Biosciences Inc. | 5.04% | 1,438,975 | $8.8M | — |
| ELDN Eledon Pharmaceuticals Inc. | 1.93% | 814,980 | $3.4M | — |
| LVTX Lava Therapeutics NV | 1.05% | 1,919,455 | $1.8M | — |
| INZY Inozyme Pharma Inc. | 0.70% | 443,255 | $1.2M | — |
| QTTB Q32 Bio Inc. | 0.48% | 244,083 | $840K | — |
Portfolio Sells Q4 2024
No earlier filing to compare with.
Portfolio Buys Q4 2024
No earlier filing to compare with.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 10 | $534.0M | MGTX, INBX, NVAX, ANAB, ODTX |
| Q1 2026 | 9 | $336.0M | MGTX, INBX, NVAX, ANAB, AGMB |
| Q4 2025 | 8 | $310.4M | MGTX, INBX, NVAX, ANAB, IMRX |
| Q3 2025 | 9 | $260.4M | MGTX, NVAX, INBX, ANAB, IMRX |
| Q2 2025 | 10 | $175.7M | MGTX, NVAX, ANAB, INBX, OMDA |
| Q1 2025 | 9 | $165.9M | MGTX, NVAX, INBX, ANAB, ELDN |
| Q4 2024 | 9 | $174.4M | MGTX, NVAX, INBX, ANAB, IGMS |